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Apoptosisa b s t r a c t
The germinal center (GC) is a dynamic microenvironment where antigen (Ag)-activated B cells
rapidly expand and differentiate, generating plasma cells (PC) that produce high-afﬁnity antibodies.
Precise regulation of survival and proliferation of Ag-activated B cells within the GC is crucial for
humoral immune responses. The follicular dendritic cells (FDC) are the specialized stromal cells
in the GC that prevent apoptosis of GC-B cells. Recently, we reported that human GC-B cells consist
of CD9+ and CD9 populations and that it is the CD9+ cells that are committed to the PC lineage. In
this study, we investigated the functional role of CD9 on GC-B cells. Tonsillar tissue section staining
revealed that in vivo CD9+ GC-B cells localized in the light zone FDC area. Consistent this, in vitro
CD9+ GC-B cells survived better than CD9 GC-B cells in the presence of HK cells, an FDC line, in a
cell–cell contact-dependent manner. The frozen tonsillar tissue section binding assay showed that
CD9+ GC-B cells bound to the GC area of tonsillar tissues signiﬁcantly more than the CD9 GC-B cells
did and that the binding was signiﬁcantly inhibited by neutralizing anti-integrin b1 antibody.
Furthermore, CD9+ cells bound to soluble VCAM-1 more than CD9 cells did, resulting in activation
and stabilization of the active epitope of integrin b1. All together, our data suggest that CD9 on GC-B
cells contributes to survival by strengthening their binding to FDC through the VLA4/VCAM-1 axis.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction lacking CD37 and CD81 showed that these tetraspanins on B cellsTetraspanins are a large superfamily of proteins with four
highly conserved transmembrane domains [1]. Tetraspanins inter-
act with one another and many other proteins, organize a network
of molecular interactions into functional microdomains, and regu-
late cellular process in which the associated proteins are involved
[2,3]. The list of tetraspanin-associated proteins is growing and
includes integrins and other adhesion molecules, proteins with
Immunoglobulin (Ig) domains, enzymes (e.g., ectopeptidases and
metalloproteases), and intracellular signaling molecules (e.g.,
heterotrimeric G proteins, PI4K, activated PKC) [4]. In immune
cells, tetraspanins interact with key leukocyte receptors such as
the B cell receptor (BCR) complex, CD4/CD8, MHC molecules, and
integrins, and thus modulate leukocyte receptor activation and
downstream signaling pathways [5]. Recent studies with miceare important in the humoral immune response [5]. CD37 on B cell
supports long-lived plasma cell survival by orchestrating the
VLA4-AKT signaling axis [6], while CD81 on B cells organizes
CD19, which is required for the effective BCR signaling [7]. In con-
trast, the tetraspanins CD9, CD151, and Tssc6 appeared to be dis-
pensable in the B cell immune response [5]. The functions of
tetraspanins in the human B cell-mediated immune response,
however, have not been largely explored yet. Recently, we reported
that CD9 is expressed in a subset of the human tonsillar germinal
center (GC) B cells but not in naïve and memory B cells [8]. The
speciﬁc expression of CD9 on human GC-B cells in contrast to
mouse GC-B cells that do not express CD9 [9] suggests that CD9
on human GC-B cells may have a functional role in the GC
microenvironment.
The GC is a specialized microenvironment where high-afﬁnity
antibody-secreting plasma cells (PC) and memory B cells are
generated. Recently introduced imaging approaches advanced
our understanding of the germinal center as a highly dynamic
structure in which B cells move around and interact with other
neighboring cells to produce B cells with high afﬁnity [10,11].
Following the BCR stimulation by antigens, B cells migrate into
the GC and rapidly proliferate within the GC microenvironment
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phase of rapid proliferation, antibody diversiﬁcation processes
such as somatic hypermutation and class-switch recombination
take place. Somatic hypermutation introduces point mutations
into the IgV gene and class-switch recombination alters the effec-
tor function of the antibody by switching the constant region of
IgM to the IgG, IgE, or IgA isotypes. Subsequently, newly mutated
cells expressing high-afﬁnity BCR against antigen on FDC are
selected and subsequently present this antigen to T cells for further
selection. During the selection process by BCR, the B cells are
programmed to die unless survival signals are provided from FDC
[12]. While several adhesion molecules and soluble factors from
FDC have been reported as promoting GC-B cell survival [13], phys-
ical interactions appeared to be necessary for FDC-mediated GC-B
cell survival [14]. Adhesion molecules such as ICAM-1 and
VCAM-1 on FDC mediate the anti-apoptotic FDC effect on GC-B
cells [15].
Here, we investigated the functional role of CD9 on B cells with-
in the GC microenvironment using human tonsillar GC-B cells,
which consists of CD9 and CD9+ populations [8]. CD9 expression
on human GC-B cells enhances the afﬁnity of VLA4 to VCAM-1 on
FDC. The strong adhesion of GC-B cells to FDC is promoted by CD9,
which in turn contributes to better survival of GC-B cells.
2. Results
2.1. CD9+ GC-B cells reside in the FDC area of the light zone of the GC
The interactions between GC-B cells and FDC are essential for
GC-B cell survival and differentiation [13]. Since CD9 is implicated
in the cell–cell interaction [16–18], we hypothesized that CD9 onFig. 1. Immunoﬂuorescent staining for CD9 in the germinal centers of human tonsil
combination with anti-CD23 (A, green), anti-CD54 (B, green), and anti-Ki67 (C, green). (Fo
to the web version of this article.)GC-B cells may play a role in the interaction between GC-B cells
and FDC. To address this question, we ﬁrst determined whether
CD9+ GC-B cells were located in the FDC area in vivo. Previously,
we demonstrated that tonsillar GC-B cells were composed of
CD9+ and CD9 populations and that this ratio was various from
donor to donor [8]. Consistent with our previous observation, a
portion of CD10+ GC-B cells expressed CD9 when tonsillar tissue
sections were stained with anti-CD10 and anti-CD9 antibodies
(Supplemental Fig. 1). The tonsillar tissue sections were further
stained with antibodies against FDC markers in combination with
anti-CD9 to determine whether CD9+ GC-B cells were situated in
the FDC area (Fig. 1A and B). Among FDC markers, CD23 and
CD54 were selected because CD23+ FDC and CD54+ FDC reside in
the light zone of the GC, where FDC are abundant [19]. CD9+ cells
were localized both in the apical and basal light zones of the GC
where CD23+ and CD54+ FDC, respectively, reside [20]. Further-
more, the majority of CD9+ cells did not express Ki-67, a marker
for centroblasts of the dark zone area (Fig. 1C). Although CD9+
and Ki-67+ cells were not mutually exclusive, the staining pattern
showed that CD9+ cells and Ki-67+ cells occupied two distinctive
areas, conﬁrming that CD9+ cells were located in the light zone
of the GC. The stainings were speciﬁc because no expression was
observed in tonsillar tissue sections stained with corresponding
control antibodies (data not shown). These data suggest that
CD9+ GC-B cells are in close contact with FDC in vivo.
2.2. CD9+ GC-B cells survive better than CD9 GC-B cells in the
presence of FDC/HK cells in a cell–cell contact-dependent manner
The in vivo location of CD9+ GC-B cells in the FDC area
prompted us to determine whether CD9 has a functional role ins. The frozen tonsillar tissue sections were stained with anti-CD9 (A–C, red) in
r interpretation of the references to color in this ﬁgure legend, the reader is referred
Table 1
Percentage of surviving CD9+ GC-B cells in the presence or absence of HK cells.
Day of
culture
CD9+ GC-B cells (%)
Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5
Day 0 58.5 26.2 48.5
Day 1 HK 30.5 39.9 21.4 26.1 58.7
+HK 59.0 54.2 41.0 33.5 71.1
+HK (transwell) 27.3 22.8 57.8
GC-B cells were cultured with CD40L in the presence or absence of HK cells for 24 h.
In some experiments, GC-B cells are separated from HK cells by transwell inserts. At
the end of the culture, cells were stained with anti-CD9 or isotype control antibody
and analyzed by ﬂow cytometry. Percentage of the surviving CD9+ GC-B cells was
determined.
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tion in vitro, we utilized an FDC line, HK cells [21]. Like FDC, HK
cells prevented GC-B cells from spontaneous apoptosis [22,23].
Therefore, we hypothesized that CD9 expression on GC-B cells
may provide a survival advantage by interacting with FDC/HK cells.
GC-B cells were ﬁrst isolated and CD9+ and CD9 GC-B cell
populations were further separated using a MACS column. Each
population was cultured with CD40L in the presence or absence
of HK cells for 24 h, and apoptosis was measured. As shown in
Fig. 2A and B, CD9+ GC-B cells consistently survive better than
CD9 cells in the presence of HK cells. However, the percentage
of Annexin V+ cells (early and late apoptotic cells) in CD9+ and
CD9 GC-B cells was comparable in the absence of HK cells. These
data suggested that CD9 and CD9+ cells were not intrinsically
different in propensity to apoptosis but rather CD9+ cells survive
better while in interaction with FDC/HK cells. Greater survival of
the CD9+ population compared to the CD9 population in the
presence of FDC/HK cells was not attributed to the anti-CD9 anti-
body bound to CD9+ GC-B cells during the separation procedure
because the anti-CD9 antibody (clone 10E5) did not affect cell sur-
vival when added in the culture of GC-B cells (Supplemental Fig. 2).
To be more secure in our conclusion that the anti-CD9 antibody
bound to CD9+ GC-B cells during separation procedure did not
enhance CD9+ GC-B cell survival in the presence of HK cells, we
assessed HK dependency of CD9+ GC-B cells with another method.
GC-B cells without separation by CD9 were cultured with CD40L
in the presence or absence of HK cells and 24 h later, the surviving
GC-B cells were examined for CD9 expression. Regardless of
donors, the percentage of the surviving CD9+ GC-B cells was
consistently higher in the presence of HK cells than in the absenceFig. 2. CD9+ GC-B cells survive better than CD9 GC-B cells in the presence of FDC/HK cel
absence of HK cells for 24 h, and Annexin V-FITC and PI binding were measured by ﬂo
presence or absence of HK cells for 24 h. In some experiments, GC-B cells were separated
either anti-CD9 or isotype control antibodies and analyzed by ﬂow cytometry. The percof HK cells (Fig. 2C and Table 1), conﬁrming that CD9+ GC-B cells
survived better than CD9 GC-B cells with FDC/HK cells. To further
determine whether CD9+ GC-B cells survive better than CD9 GC-B
cells in the presence of HK cells through cell–cell contacts, we per-
formed transwell experiments (Fig. 2C and Table 1). When GC-B
cells were separated fromHK cells by transwell inserts, the percent-
age of surviving CD9+ GC-B cells decreased to a level similar to that
of CD9+ GC-B cells in the absence of HK cells, suggesting that direct
contactwith FDC/HK cells is essential for the CD9-mediated survival
advantage in CD9+ GC-B cells. The physical contact of CD9+ GC-B
cells and FDC/HK cells appeared not to bemediated via ECMbecause
ﬁbronectin and laminin-produced by FDC/HK cells could not rescue
the CD9+ GC-B cell population (Supplemental Fig. 3).ls. (A and B) CD9+ and CD9 GC-B cells were cultured with CD40L in the presence or
w cytometry to assess apoptosis. (C) GC-B cells were cultured with CD40L in the
from HK cells by transwell inserts. At the end of the culture, cells were stained with
entage of the surviving CD9+ GC-B cells was determined.
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inhibited by anti-integrin b1 antibody
Numerous studies have shown that CD9 forms a complex with
integrin b1 and promotes integrin-based functions [24–28]. In
addition, the interaction between GC-B cells and FDC through
VLA4/VCAM-1 is essential for GC-B cell survival [15]. Hence, we
hypothesized that the CD9 on GC-B cells contributes to FDC-
mediated GC-B cell survival through VLA4/VCAM-1 interaction.
To determine whether the CD9 on GC-B cells is involved in the
interaction with FDC, we performed a frozen section binding assay,
which was reportedly useful in showing that human B cells adhere
to FDC in the GC through VLA4–VCAM1 interaction [29,30]. First,
tonsillar tissue sections were incubated with Calcein-AM-labeled
CD9+ or CD9 GC-B cells for 30 min. Then, the bound cells were
observed under a ﬂuorescent microscope after washing. As shown
in Fig. 3Ai and Aii, signiﬁcantly more CD9+ GC-B cells bound to the
GC area of tonsillar tissues than did CD9 GC-B cells. The greater
binding of CD9+ GC-B cells to the tonsillar tissue sections was
not attributable to the anti-CD9 antibody bound to CD9+ GC-B cells
during separation procedure because the anti-CD9 antibody did
not enhance unseparated GC-B cell binding when incubated before
applied to the tonsillar tissue (Supplemental Fig. 4). Next, we
determined whether the binding of CD9+ GC-B cells to the GC area
of tonsillar tissues was mediated by integrin. When CD9+ GC-B
cells were preincubated with a neutralizing anti-integrin b1 anti-
body, their binding to tonsillar tissues was dramatically inhibited
compared to preincubation with an isotype control antibody
(Fig. 3Aiii and Aiv), suggesting that integrin b1 is involved in
CD9+ GC-B cell binding to FDC.Fig. 3. The binding of CD9+ GC-B cells to the tonsillar tissue section is inhibited by the an
Calcein-AM and then applied to the tonsillar tissue sections. Slides were then examined
GC-B cells preincubated with an isotype control antibody, and (iv) CD9+ GC-B cells
independent experiments are shown. (B) GC-B cells were stained with anti-CD9, anti-CD2
of CD29 and CD49d in CD9 GC-B cells and CD9+ GC-B cells, respectively. Filled histogrTo determine whether the quantitative difference in VLA4
expression of CD9 and CD9+ GC-B cells accounts for their differ-
ence in GC binding, we examined VLA4 expression in the two
populations (Fig. 3B). FACS staining revealed no quantitative differ-
ence in either integrin a4 (CD49d, clone 9F10) or integrin b1 (CD29,
clone Mar4) expression between the two populations. This ﬁnding
was conﬁrmed using additional anti-CD49d (clones 2B4) and
anti-CD29 (clones P5D2 and TDM29) antibodies (data not shown).
These data suggest that the two populations may be different in
afﬁnity or avidity of VLA4 for its ligand, VCAM-1.
2.4. CD9 may facilitate VCAM-1 binding by enhancing the exposure of
high-afﬁnity conformational epitope of VLA4
To determine whether CD9 is involved in the integrin-mediated
binding of CD9+ GC-B cells, we attempted to knock down CD9 in
CD9+ GC-B cells. However, we were unsuccessful because of the
fragile nature of GC-B cells. Hence, we took advantage of a human
B lymphoma cell line of GC origin, L3055 cells [31]. We previously
reported the differential CD9 expression in two clones from the par-
ent L3055 cells [32]. Analogous to GC-B cells, the CD9+ L3055-12
clone is more FDC/HK cell-dependent for its survival than CD9
L3055-33 [32]. FACS staining revealed that both CD9+ L3055-12
and CD9 L3055-33 expressed CD29 and CD49d with no quantita-
tive difference between them, just as GC-B cells did (Fig. 4A).
First, we compared CD9+ L3055-12 to CD9 L3055-33 for the
binding capacity to soluble VCAM-1, which is known to bind to
only high-afﬁnity VLA4 integrin [33]. As shown in Fig. 4B, the
CD9+ L3055-12 clone bound to soluble VCAM-1 greater than did
the CD9 L3055-33 clone. This binding was speciﬁc because theti-integrin b1 antibody. (A) CD9+ and CD9 GC-B cells were internally labeled with
under a ﬂuorescent microscope: (i) CD9 GC-B cells, (ii) CD9+ GC-B cells, (iii) CD9+
preincubated with an anti-integrin b1 antibody. Representative data from two
9, and CD49d. Histograms with broken and solid lines indicate the expression levels
ams indicate isotype control.
Fig. 4. CD9 is involved in optimal VCAM-1 binding and modulation of the integrin activation state. (A) L3055-12 and L3055-33 were stained with anti-CD9, anti-CD29, and
CD49d. Histograms with broken and solid lines indicate isotype control and speciﬁc antibody, respectively. (B) The binding of soluble VCAM-1-Fc (10 lg/mL) by L3055-12 and
L3055-33 was measured by ﬂow cytometry. Competition experiments were performed to conﬁrm the binding speciﬁcity by incubating neutralizing anti-VCAM-1 with
VCAM-1-Fc for 30 min before being added to L3055-12 cells. Histograms with broken and solid lines indicate the binding to 41BB-Fc (negative control) and VCAM-1-Fc,
respectively. The ﬁlled histogram indicates the binding to VCAM-1-Fc after the preincubation with anti-VCAM-1. (C) L3055-12 and L3055-33 were stained with anti-CD29
(clone MAR4, total CD29 expression, ﬁlled histograms) and anti-CD29 (clone HUTS21, activated form of CD29 expression, empty histograms) following incubation with
41BB-Fc (negative control) and VCAM-1-Fc. Histograms with a broken line indicate the isotype control.
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soluble VCAM-1 was pre-incubated with anti-VCAM-1 antibody.
Next, we attempted to determine whether the greater binding of
CD9+ L3055-12 to VCAM-1 is attributed to the high-afﬁnity confor-
mational state of VLA4. It has been reported that VLA4 exposes a
certain conformational epitope called hybrid domain epitope, upon
ligand occupation [34]. The exposure of this epitope, recognized by
mAb HUTS21 [35], can be used to determine the VLA4 ligand bind-
ing afﬁnity [36]. As expected, mAb HUT21 binding was not
detected either in the CD9+ L3055-12 clone or the CD9 L3055-
33 clone when the cells were incubated with a negative control
ligand, 41BB. However, the epitope was readily detectable after
incubation with soluble VCAM-1 (Fig. 4C). The HUT21 mAb binding
was quantitatively different between the two clones. CD9+ L3055-
12 showed signiﬁcantly higher binding than CD9 L3055-33 did
(Fig. 4C). Total CD29 expression did not change after binding of
soluble VCAM-1 (Fig. 4C). All together, these data suggest that
CD9 on B cells facilitates VCAM-1 binding by enhancing exposure
of high-afﬁnity conformational epitope of VLA4.3. Discussion
Tetraspanins play a role as molecular facilitators, enhancing the
function of the associated molecules [1]. Although it has been
reported that tetraspanin CD9 is associated with integrins and
facilitates the integrin-mediated functions [24–28], this is the ﬁrst
report suggesting that CD9 may contribute to VLA4-mediated
VCAM-1 binding in human mature B cells. Previously, the
functional role of two other tetraspanins, CD37 and CD81 in
VLA4-mediated VCAM-1 binding of murine B cell has been
reported [6,37]. Although both molecules increased VLA4 avidity
to its ligands, their underlying mechanisms appeared to be slightly
different. While CD37 increased VLA4 afﬁnity to its ligand as well
as increased the avidity by inducing VLA4 clusters at the ligand
contact site [6], CD81 derived high VLA4 avidity to ligand upon
ligand binding in an afﬁnity independent manner [37]. Here, we
present evidence that CD9 may enhance VLA4-mediated VCAM-1
binding by increasing VLA4 afﬁnity. It seems that CD9 expression
facilitates the exposure of high-afﬁnity conformational epitope of
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bility that CD9 induces VLA4 clusters at the ligand contact site to
strengthen the interaction as well.
Overall, it seems that CD9, CD37, and CD81 have redundant
functions in enhancing VLA4-mediated adhesion to VCAM-1. Then,
how do cells properly utilize different tetraspanins to do the same
process? A simple answer would be the differential expression of
tetraspanins in cells. Indeed, Barrena et al. reported that human
B cells from different developmental stages have unique expres-
sion patterns of tetraspanin proteins [38]. Worth mentioning is
that human GC-B cells are reported to express CD81 and CD37
homogeneously, different from CD9 [39,40]. Taken together, it is
tempting to speculate that CD9 further optimizes VCAM-1 binding
by VLA4 that was modulated by CD81 and CD37. The human GC-B
cell adhesion to FDCs without CD9 may be transient and weak
while CD9 enhances the adhesion of GC-B cells to FDCs in a strong
and sustained manner by stabilizing the VLA4–VCAM-1 interaction
through conformational changes of VLA4. The strong adhesion
mediated by CD9 in turn may contribute to GC-B cell survival.
Indeed, we found that CD9+ GC-B cells survived better than
CD9 GC-B cells only when FDCs/HK cells are present in the cul-
ture. These data strongly suggest that CD9 is involved in the inter-
action with FDC. Although we presented evidence supporting the
involvement of CD9 in VLA4-mediated ﬁrm adhesion to VCAM-1
and subsequent survival, our current study has a limitation. It is
possible that CD9+ GC-B cells and CD9 GC-B cells have more dif-
ferences than CD9 expression, which may contribute to different
capacities of these two populations in their adhesion and survival.
To clarify the direct role of CD9 in the process, searching for neu-
tralizing anti-CD9 antibodies as well as knocking down the CD9
gene in B cells of GC-origin are underway.
In summary, CD9 expression in human GC-B cells may have a
functional role in enhancing the afﬁnity of VLA4 to VCAM-1 on
FDC in the light zone of the GC. The strong adhesion mediated by
CD9 contributes to better survival of GC-B cells and may give a fur-
ther advantage over the ongoing selection process in the light zone
of the GC.4. Materials and methods
4.1. Antibodies and reagents
FITC- or PE-conjugated anti-CD9 (clone MM2/57) and FITC-
conjugated anti-CD29 (clone TDM29) were from Southern Biotech
(Birmingham, AL); PE-conjugated anti-CD10, anti-CD23, anti-
CD54, anti-CD29 (clones MAR4 and HUTS21), and anti-CD49d
(clone 9F10) were from BD Biosciences (San Jose, CA); FITC-
conjugated anti-His and rat anti-mouse IgG1 microbeads were
from Miltenyi Biotec (Sunnyvale, CA); FITC-conjugated anti-CD29
(clone P5D2) were from Santa Cruz Biotech (Santa Cruz, CA); FITC-
conjugated anti-Ki-67 was from Zymed (Carlsbad, CA); Anti-
CD49d (clone 2B4) was from R & D Systems (Minneapolis, MN).
Anti-CD9 (clone 10E5) was a kind gift from Dr. J.C. Choe
(Department of Microbiology and Immunology, Kangwon National
University School of Medicine, Chunchon, Korea). Soluble human
CD40L was generously provided by Dr. R. Armitage (Amgen Corpo-
ration, Seattle, WA).
4.2. Immunoﬂuorescence
Cryosections of human tonsils (5 lm thick) were air-dried over-
night at room temperature and ﬁxed in cold acetone for 10 min.
Nonspeciﬁc binding of the antibody was blocked by incubating
the slides with 1% BSA-PBS for 30 min at room temperature in a
humidiﬁed chamber. Slides were incubated with anti-CD9-FITCin combination with anti-CD10-PE, anti-CD23-PE, or anti-CD54-
PE or with anti-CD9-PE in combination with anti-Ki-67-FITC.
Isotype control-FITC and isotype control-PE were used side by side
to exclude false positives. Slides were washed and mounted with
anti-fade mounting medium (Invitrogen, Carlsbad, CA). Slides were
then examined and images collected on a deconvolution micro-
scope (Axiovert 200M; Carl Zeiss Microimaging, Jena, Germany).
Images were processed using the SlideBook software (Intelligent
Imaging Innovations, Denver, CO).
4.3. Preparation of GC-B cells and apoptosis assay
Tonsils were obtained from the Surgery Department within the
Ochsner Clinic Foundation. Informed consent was not required
because these materials are considered to be waste generated dur-
ing surgery by Institutional Review Board. GC-B cells were isolated
from the tonsils and further separated by CD9 expression as
described previously [8].
For apoptosis assay, CD9+ and CD9 GC-B cells (3–5  105 cells/
well) were cultured in 12-well plates either in the presence of
CD40L (100 ng/mL) alone or in the presence of CD40L plus irradi-
ated FDC/HK cells (4  104 cells/well; 5000 rad) for 24 h. HK cells
were maintained as described previously [21]. The GC-B cells were
collected, stained with Annexin V-FITC and propidium iodide (PI)
according to the manufacturer’s protocol (BD Biosciences), and
subjected to ﬂow cytometric analysis.
4.4. Flow cytometry
Cells were stained with a panel of antibodies directly conju-
gated with PE or FITC by incubating at 4 C for 15 min. After wash-
ing with PBS containing 0.2% BSA and 0.1% sodium azide, cells were
ﬁxed with 1% paraformaldehyde and analyzed by ﬂow cytometry.
4.5. Frozen section binding assay
In vitro frozen section binding assay was performed as
described by Freedman et al. [29,30]. In short, GC-B cells were
labeled with 1 lM Calcein AM (Invitrogen) for 15 min at room
temperature in PBS. Cells were washed twice with serum contain-
ing media and resuspended at 3  107 cells/mL. One hundred
microliters of the cell suspension were placed onto frozen sections
of tonsil and incubated at 37 C for 30 min. After incubation, slides
were ﬁxed in 3% glutaraldehyde in PBS overnight at 4 C. Slides
were washed, mounted with anti-fade mounting medium contain-
ing DAPI (Invitrogen), and then examined by ﬂuorescence micros-
copy. For blocking experiments, cells were preincubated with
neutralizing anti-integrin b1 (R & D Systems) or isotype control
antibodies (10 lg/mL) for 30 min before applying to tissue
sections.
4.6. sVCAM-1 binding and detection of an activated form of CD29
L3055 cell subclones L3055-12 and L3055-33 were maintained
as described previously [32]. L3055-12 and L3055-33 (5  105 cells
per 100 lL of the complete media) were incubated with soluble
VCAM-1-His Tag (10 lg/mL, R & D systems) at 37 C for 30 min.
Binding of soluble VCAM-1 was detected by incubating the cells
with the FITC-conjugated anti-His antibody for 20 min at 4 C. As
a negative control, the same amount of soluble 41BB-His Tag (R
& D systems) was added. In some experiments, soluble VCAM-1
was preincubated with neutralizing anti-VCAM-1 antibody
(10 lg/mL, Beckman Coulter, Indianapolis, IN) before incubation
with the cells. To detect an activated form of CD29, the cells were
incubated with soluble VCAM-1, followed by staining with PE-
conjugated anti-CD29 (clone, HUTS21).
376 S.-O. Yoon et al. / FEBS Open Bio 4 (2014) 370–3764.7. Statistical analysis
Statistical analysis and graphic presentation were carried out
with GraphPad Prism 4.0 (GraphPad, La Jolla, CA). Results are
presented as means of triplicate assays plus SEM. The statistical
signiﬁcance of differences was determined by Student’s t-test;
P < 0.05 was considered signiﬁcant.
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